Skip to main content
. 2021 Sep 6;599(7883):114–119. doi: 10.1038/s41586-021-03944-y

Fig. 1. Rapid expansion of Delta variant B.1.617.2 cases in India and reduced sensitivity to neutralizing antibodies from sera derived following infection and vaccination.

Fig. 1

a, Proportion of lineages in incident cases of SARS-CoV-2 in India 2020–2021. b, Surface representation of the SARS-CoV-2 B.1.671.2 spike trimer (PDB: 6ZGE). Red, L19R; green, del157/158; blue, L452R; yellow, T478K. The white dotted box indicates the location of the D950N substitution (orange). c, Neutralization of the Delta variant by convalescent human serum from mid-2020. Fold change in serum neutralization of 100 TCID50 of B.1.17 (Alpha), B.1.351 (Beta) and B.1617.2 (Delta) variants relative to WT (IC19); n = 12. Shown is the ID50, the serum dilution required for 50% virus inhibition, expressed as GMT (from technical replicates) with s.d. d, Neutralization of B.1617.2 live virus by sera from vaccinated individuals (n = 10 ChAdOx1 or n = 10 BNT12b2), compared with B.1.1.7 and Wuhan-1 WT. The graph presents the average of two independent experiments. e, Neutralization of B.1.617 spike PV and WT (Wuhan-1 D614G) by vaccine sera (n = 33 ChAdOx1 or n = 32 BNT162b2). The data are representative of two independent experiments each with two technical replicates. *P < 0.05, **P < 0.01, ****P < 0.0001 (Wilcoxon matched-pairs signed rank test); NS, not significant.